Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...

Rogaine was approved by the Food and Drug Administration in 1988, the first drug to win the agency’s endorsement for male ...

Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after ...

Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular ...

Sarepta Therapeutics's revenues have an average growth rate of 29.5% with operating expenses growing at 14.4%. The company's ...

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death ...

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...

Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

The plan put forth Tuesday could see the Sackler family pay up to $7 billion. Also in the news: Merck prepares to close its manufacturing plant in Pennsylvania; Optum Rx, which includes UnitedHealth ...

Mizuho views the selloff in shares of Sarepta (SRPT) yesterday due to concerns about Elevidys adoption as a result of the fatal acute liver ...